🇯🇵·8h agoIndustry
Roche’s Announcement Regarding divarasib (Announcement of Phase III Krascendo1 Study Results)
Publisher
C
Chugai Pharmaceutical
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Chugai Pharmaceutical
- Region
- Japan
- Scope
- Industry
- Published
- July 2, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on chugai-pharm.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Chugai Pharmaceutical
Scope: Industry
Related coverage
More related coverage
Chugai Pharmaceutical News/8h ago
ロシュ社によるdivarasibに関する発表について（第III相Krascendo1試験結果）
Roche Newsroom/10h ago
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
Otsuka Holdings RSS/15h ago
Taiho Innovations Begins Operations Under New Organizational Structure Establishing an Early Clinical Development Function to Strengthen Its Co-Creation Platform
Otsuka Holdings RSS/15h ago